Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

• ClinicalTrials.gov Identifier: NCT05712694
• Recruitment Status: Recruiting
• First Posted: February 3, 2023
• Last Update Posted: December 7, 2023
• Sponsor: Polaris Group
• Information provided by (Responsible Party): Polaris Group

Study Description

Brief Summary:

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Condition or disease	Intervention/treatment	Phase
Soft Tissue Sarcoma	Drug: ADI PEG20; Other: Placebo	Phase 3

Detailed Description:

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 300 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
• Masking: Triple (Participant, Care Provider, Investigator)
• Masking Description: This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial
• Primary Purpose: Treatment
• Official Title: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial
• Actual Study Start Date: November 29, 2023
• Estimated Primary Completion Date: December 30, 2027
• Estimated Study Completion Date: December 30, 2027

Arms and Interventions

Arm	Intervention/treatment
Experimental: ADIGemDoc; ADI-PEG 20: 36 mg/m2 on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 600 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 60 mg/m2 on day 8 of each 21-day cycle	Drug: ADI PEG20; Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS); Other Name: Pegargiminase
Placebo Comparator: PBOGemDoc; Placebo: matched PBO on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 900 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 75 mg/m2 on day 8 of each 21-day cycle	Other: Placebo; Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)

Outcome Measures

Primary Outcome Measures :

1. Primary End Point of PFS [ Time Frame: Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years). ]
   The primary objective is to compare the primary endpoint of PFS in subjects treated with the arginine degrading enzyme ADI-PEG 20 plus Gem and Doc (ADIGemDoc) or PBO plus Gem and Doc (PBOGemDoc) in the 2nd or 3rd line setting using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by blinded independent central review committee (BICR)

Secondary Outcome Measures :

1. Secondary End Point of ORR (CR+PR) [ Time Frame: Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years). ]

   The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to:

   Objective response rate (ORR) (complete response [CR] + partial response [PR]) The secondary endpoint of ORR will be assessed by BICR using RECIST 1.1 and tested using a CMH test stratified by the stratification factors used during the randomization based on the ITT population.

2. Secondary End Point of Overall Survival (OS) [ Time Frame: Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years). ]

   The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to:

   OS

   The secondary endpoint of OS will be tested using a log-rank test stratified by the stratification factors used during the randomization based on the ITT population. A stratified Cox model will be used to estimate HR and 95% CI, and KM curves will be used to estimate OS median and 95% CI.

3. Secondary End Point of Safety and Tolerability [ Time Frame: Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years). ]
   All clinically significant abnormalities and deteriorations will be followed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE V5).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• A subject will be eligible for study participation if he/she meets the following criteria:

  1. Histologically or cytologically confirmed, grade 2 or 3, LMS STS that would be standardly treated with Gem or GemDoc.
  2. Determination of LMS subtype: uterine or non-uterine.
  3. Measurable disease per RECIST 1.1 (Appendix A), defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam.
  4. Previous treatment with up to 2 systemic regimens, including at least 1 systemic regimen containing doxorubicin.
  5. Treatment > one year ago in the adjuvant/neoadjuvant setting with Gem or Doc is allowed.
  6. Age >18 years.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of < 1 at enrollment (Appendix B).
  8. Leukocytes ≥ 3,000/mcL.
  9. Absolute neutrophil count ≥ 1,500/mcL.
  10. Platelets ≥ 100,000/mcL.
  11. Total bilirubin ≤ 2 x ULN. (≤ 3 x ULN for potential subjects with Gilbert's Disease)
  12. AST(SGOT)/ALT(SGPT) ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
  13. Creatinine clearance ≥ 60 mL/min (by Cockcroft-Gault equation).
  14. Serum uric acid ≤ 8 mg/dL (with or without medication control).
  15. QTc interval range from 350 to 450 ms for adult men and from 360 to 460 ms for adult women.
  16. Subjects and their partners must be asked to use appropriate contraception. They must agree to use 2 forms of contraception or agree to refrain from intercourse for the duration of the study and for 35 days after the last dose of ADI-PEG 20 or for at least 3 months (male subjects) or 6 months (female subjects) after treatment with gemcitabine, whichever is the longer duration.
  17. Ability to understand and willingness to sign the informed consent form.
  18. No concurrent investigational drug studies are allowed.

Exclusion Criteria:

• A subject will not be eligible for study participation if he/she meets any of the exclusion criteria:

  1. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present in the opinion of the Investigator will not affect subject outcome in the setting of current diagnosis.
  2. Currently receiving other investigational agents.
  3. Prior treatment with ADI-PEG 20, Gem or Doc. Patients treated > one year ago in the adjuvant/neoadjuvant setting with Gem or Doc are allowed to be enrolled.
  4. Known brain metastases. Such patients must be excluded from this trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, Gem, Doc, polysorbate 80, pegylated compounds, or other agents used in this study.
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  7. History of seizure disorder not related to underlying cancer.
  8. Grade 2 or higher neuropathy.
  9. Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
  10. Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study treatment. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Contacts and Locations

Contacts

Contact: Mirla Langlois; 858-452-6688 ext 161; mlanglois@polarispharma.com

Contact: Stephanie V Rumund; 858-452-6688; svanrumund@polarispharma.com

Locations

United States, Missouri

Washington University School of Medicine - Siteman Cancer Center; Recruiting

Saint Louis, Missouri, United States, 63110

Contact: Brian Van Tine, MD 314-362-7997 bvantine@wustl.edu

Principal Investigator: Brian Van Tine, MD

Sponsors and Collaborators

Polaris Group

Investigators

• Study Director: John S Bomalaski; Polaris Group

More Information

• Responsible Party: Polaris Group
• ClinicalTrials.gov Identifier: NCT05712694
• Other Study ID Numbers: POLARIS2022-001
• First Posted: February 3, 2023
• Last Update Posted: December 7, 2023
• Last Verified: December 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Polaris Group:

Soft Tissue Sarcoma; Arginine; Arginine Deiminase; ADI-PEG 20; Pegargiminase; Leiomyosarcoma

Additional relevant MeSH terms:

Sarcoma; Leiomyosarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Muscle Tissue